Before self-injecting, we always recommend seeking professional instruction from a certified healthcare practitioner
Evidence-Base Disclosure The published evidence base for AOD-9604 consists predominantly of preclinical research animal models (often rats or mice) and in vitro cell-culture experiments
human bioavailability is unknown Subcutaneous injection Human subcutaneous bioavailability and pharmacokinetics are unknown Factor Convenience Oral capsules No mixing or syringe math Subcutaneous injection Requires reconstitution, sterile supplies, and injection-site planning Factor Evidence limits Oral capsules No controlled human dose, benefit, or safety trial Subcutaneous injection No controlled human dose, benefit, or safety trial Factor Can the amounts be treated as equal
For individuals who are sensitive to needles, this might also help minimize the pain levels you are going to experience when injecting the needle
Because it does not activate the hGH receptor (fully) and does not elevate IGF-1 in human trials, it avoids many of the growth-hormone-related side effects (such as insulin resistance) seen with full hGH therapy